Quarterly ResultMay 6, 2026, 04:29 PM
Tenaya Therapeutics Q1 Net Loss Narrows to $19.3M; Alnylam Deal
AI Summary
Tenaya Therapeutics reported a reduced net loss of $19.3 million for Q1 2026, down from $26.9 million in Q1 2025, driven by lower operating expenses and the initiation of collaboration revenue. The company also entered a significant collaboration agreement with Alnylam Pharmaceuticals, Inc., which includes an upfront platform access fee of up to $10.0 million and potential future milestone payments of up to $1.1 billion. Management believes existing cash and cash equivalents of $80.9 million are sufficient to fund operations for at least the next twelve months.
Key Highlights
- Q1 2026 net loss narrowed to $19.3 million from $26.9 million in Q1 2025.
- Collaboration revenue was $0.225 million in Q1 2026, up from $0 in Q1 2025.
- Research and development expenses decreased to $14.8 million from $21.1 million year-over-year.
- General and administrative expenses decreased to $5.4 million from $6.5 million year-over-year.
- Cash and cash equivalents stood at $80.9 million as of March 31, 2026.
- Net loss per share improved to $(0.09) from $(0.24) in Q1 2025.
- Entered collaboration with Alnylam, including up to $10.0 million upfront and $1.1 billion in milestones.
- Net cash used in operating activities decreased to $19.2 million from $23.1 million.